Japan’s Eisai Gets Preliminary Injunction Against Teva Aricept Generic
This article was originally published in PharmAsia News
Executive Summary
Japan's Eisai has managed to halt Teva Pharmaceutical plans to market a generic of Eisai's Aricept (donepezil) for treating Alzheimer's disease. Eisai said a U.S. district court issued a preliminary injunction against Teva pending the outcome of a patent-infringement suit Eisai filed against the Israeli drug maker. Eisai, whose Aricept patent does not expire until 2010, said the request for the injunction was part of its effort to "protect our intellectual property throughout the world." (Click here for more
You may also be interested in...
Eisai Fights To Maintain Aricept Patent Rights While Resuming Development On Next Generation Therapy
TOKYO - The preliminary injunction against generic company Teva Pharmaceuticals for its abbreviated new drug application pending at U.S. FDA of Japanese company Eisai's Alzheimer's drug Aricept (donepezil) will have very minimal impact on the generic drug industry as a whole, a Japanese patent lawyer told PharmAsia News
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.